Company: GANX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001558370-25-005829
Chunk: 42

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 42
---
12/23/21      |   |     174,980 | (5)​ |             — | ​    |     5.86 |   | 12/23/31   | (6)​ | —            | (8)​ | —          |
| Evan Ballantyne                |   | —             |   |           — |      |             — | (9)​ |        — |   | —          | ​    | —            | (9)​ | —          |
| Former Chief Financial Officer |   | ​             | ​ |           ​ | ​    |             ​ | ​    |        ​ | ​ | ​          | ​    | ​            | ​    | ​          |

| (1) | Subject to Mr. Mack’s continued service through each applicable vesting date, the option awards will vest and become exercisable 25% on April 5, 2025, with the remaining balance vesting and becoming exercisable in substantially equal monthly installments over the next three years left in the service period. The option awards have been granted from the 2021 Inducement Plan. |

| (2) | Subject to Mr. Fuggetta’s continued service through each applicable vesting date, the option awards will vest and become exercisable 25% on March 21, 2025, with the remaining balance vesting and becoming exercisable in substantially equal monthly installments over the next three years left in the service period. The option awards have been granted from the 2022 Plan. |

| (3) | 25% of the option awards vested and became exercisable on March 23, 2024. Starting from April 23, 2024 the option awards started vesting in substantially equal monthly installments and will continue to vest on a monthly basis subject to Mr. Fuggetta’s continued service through each applicable vesting date until the end of the four-year vesting period. The option awards have been granted from the 2022 Plan. |

29

| (4) | 25% of the option awards vested and became exercisable on July 1, 2023. Starting from August 1, 2023 the option awards started vesting in substantially equal monthly installments and will continue to vest on a monthly basis subject to Mr. Fuggetta’s continued service through each applicable vesting date until the end of the four-year vesting period. The option awards have been granted